

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

ELAINE A. RYAN (*To be Admitted Pro Hac Vice*)

PATRICIA N. SYVERSON (CA SBN 203111)

LINDSEY M. GOMEZ-GRAY (*To be Admitted Pro Hac Vice*)

2325 E. Camelback Rd. Suite 300

Phoenix, AZ 85016

eryan@bffb.com

psyverson@bffb.com

lgomez-gray@bffb.com

Telephone: (602) 274-1100

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

Manfred P. Muecke (CA SBN 222893)

600 W. Broadway, Suite 900

San Diego, California 92101

mmuecke@bffb.com

Telephone: (619) 756-7748

STEWART M. WELTMAN, LLC

Stewart M. Weltman (*To be Admitted Pro Hac Vice*)

53 W. Jackson Suite 364

Chicago, IL 60604

sweltman@weltmanlawfirm.com

Telephone: (312) 588-5033

Attorneys for Plaintiff

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

PHILLIP RACIES, On Behalf of
Himself and All Others Similarly
Situating,

Plaintiff,

v.

QUINCY BIOSCIENCE, LLC, a
Wisconsin limited liability company,

Defendant.

Case No.:

CLASS ACTION COMPLAINT FOR:

1. VIOLATION OF THE UNFAIR
COMPETITION LAW, Business and
Professions Code §17200 *et seq.*; and
2. VIOLATION OF THE
CONSUMERS LEGAL REMEDIES
ACT,
Civil Code §1750 *et seq.*

DEMAND FOR JURY TRIAL

1 Plaintiff Phillip Racies brings this action on behalf of himself and all others
2 similarly situated against Defendant Quincy Bioscience, LLC and states:

3 NATURE OF ACTION

4 1. Defendant manufactures, markets, sells and distributes Prevagen, a
5 purported brain health supplement made with the protein apoaequorin.¹ As its
6 Wikipedia cite notes, apoaequorin is used as a light emitting marker “in a broad
7 range of biological research work at the cellular level.” Through an extensive,
8 widespread, comprehensive and uniform nationwide marketing campaign, and on
9 the front of each and every Product package, where it cannot be missed by
10 consumers, Defendant represents: (1) that the Products are “clinically tested” to
11 “improve[] memory” and “support[]: healthy brain function, sharper mind, and
12 clearer thinking”; and (2) that Prevagen is “clinically tested” to “improve memory
13 within 90 days” (collectively, “the brain function and memory representations”).
14 Defendant’s brain function and memory representations are false, misleading and
15 reasonably likely to deceive the public.

16 2. Plaintiff and his counsel have retained one of the world’s foremost
17 experts in brain chemistry and an expert in the field regarding whether and how
18 substances may or may not affect brain function and memory.

19 3. He has evaluated the ingredients in Prevagen, along with reviewing the
20 summaries of purported² clinical studies that Defendant provides on its Product
21 packaging and on its website. He has concluded that: (1) Prevagen cannot work as
22 represented because apoaequorin, the only purported active ingredient in Prevagen,
23

24 ¹ Prevagen is available in regular strength (10 mg. apoaequorin), extra strength (20 mg.
25 apoaequorin) and mixed berry chewable forms (10 mg. apoaequorin) (collectively “Prevagen” or
26 “the Products”). Plaintiff reserves the right to add additional products upon completion of
discovery.

27 ² They are “purported” because there is no evidence that these studies were actually conducted,
properly conducted or that the summaries accurately reflect the actual results of the purported
28 studies.

1 is completely destroyed by the digestive system and transformed into common
2 amino acids no different than those derived from other common food products such
3 as chicken, cold cuts, hamburgers, etc.; (2) the average daily diet contains about 75
4 grams of protein, contains all the required amino acids, and has about 7,500 times
5 more amino acids than Prevagen (10 mg or 0.01 grams) and, as a result, any amino
6 acids derived from the digestion of Prevagen would be massively diluted and could
7 have no measurable effect on the brain; (3) ingestion of Prevagen cannot and does
8 not have any effect on brain function or memory; and (4) the three summaries of
9 purported clinical studies, one on the Product packaging and two on Defendant's
10 websites, apart from not being clear that these studies exist at all, are, on their face,
11 so seriously flawed that they demonstrate nothing regarding Prevagen. As a result,
12 Defendant's citation to these purported studies, particularly the one summarized on
13 the Product packaging, is a separate and distinct misrepresentation – they are cited
14 as purportedly demonstrating efficacy when, in fact, they demonstrate nothing and
15 could not since, as a matter of body chemistry, Prevagen can do nothing to enhance
16 brain function or memory.

17 4. The Prevagen packaging states that the Product is “clinically tested” to
18 provide the brain function and memory benefits. By stating that the Product is
19 clinically tested, Defendant is representing to consumers that credible scientific
20 evidence supports Defendant's claim that the Product provides the brain function
21 and memory benefits.

22 5. Reasonable consumers understand “clinically tested” to mean that
23 there is competent and reliable scientific support for the brain function and memory
24 benefit representations. However, there can never be any competent and reliable
25 scientific evidence supporting Defendant's brain function and memory
26 representations, because, as alleged herein, the apoaeguorin in Defendant's Product
27 is fully digested, broken down into common amino acids and is massively diluted
28

1 before entering the bloodstream. Furthermore, for at least the last 50 years, the
2 universally accepted form of scientific evidence recognized by experts in the field
3 for determining whether a substance provides any human health benefit is by
4 demonstrating its value over placebo through high quality and well-conducted
5 randomized controlled clinical trials (“RCTs”). Also, it is generally recognized that
6 RCTs that are of sufficient quality to be relied upon for reaching efficacy
7 conclusions should be subjected to a peer review process and published in a peer
8 reviewed journal.

9 6. A properly conducted RCT has a detailed protocol that describes how
10 the study is going to be conducted; is double blinded with a description of the
11 blinding procedures; is randomized with a description of the randomization
12 procedure; at a minimum, has primary endpoints that are described in detail;
13 contains a report section discussing all of the results; has a complete and validly
14 performed statistical analysis comparing the active ingredient to placebo; and has a
15 conclusions section that describes the results and how the active ingredient
16 compares to placebo for the previously described endpoints. On the packaging of
17 Defendant’s Product a purported study is summarized. It is a purported study
18 because, other than the grossly simplified, and thus unreliable, results summarized
19 on the packaging, there is absolutely no evidence in the public record that this study
20 was ever performed. A search of *clinicaltrials.gov* where RCTs must be registered
21 to be considered for publication in a peer reviewed journal shows that no RCT
22 involving apoeaquorin and brain function or memory was registered. Similarly, the
23 summary on the packaging contains no identifying information such that it is not
24 even clear that the study exists. There is no author identified, no title given to the
25 study and no publication identified where it may have been published. There is
26 nothing in the public record. For example, when the word apoeaquorin is searched
27 in Pub-Med, a website maintained by the NIH which contains over 24 million
28

published articles, there are 150 citations that result – none of them are studies of apoequorin and brain function or memory in humans.³ In fact, when “apoequorin” and “memory” are searched the results contain two reports – one on fly brains regarding the use of apoequorin for imaging purposes and another an in vitro study of pools of cells.⁴ As such, it is not possible to determine, at least from the label, whether the study exists and even if it does, whether it was properly conducted and properly analyzed. But, even if such a study were conducted, because apoequorin is completely digested, changed into common amino acids and massively diluted by the far larger quantity of amino acids derived from the average daily diet, there is no possible manner in which Prevagen could have any effect on brain function or memory.

7. For the same reasons, the two abstracts/summaries of purported studies purportedly conducted by Defendant summarized on Defendant’s website are not competent and reliable scientific “studies.”

8. Defendant’s brain function and memory representations are also unlawful. Prevagen is a dietary supplement. 21 U.S.C. § 321(g)(d). Dietary supplements are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA). FDA approval is not required before producing or selling a dietary supplement. However, all health benefit claims on the product package and label must be truthful and not misleading. With regard to each of the representations Defendant makes about Prevagen, this means that Defendant is required to make sure they are truthful and not misleading.

9. In order to be truthful and not misleading, dietary supplement health benefit claims must be substantiated by competent and reliable scientific evidence. 21 U.S.C. §321(r)(6)(b); Guidance for Industry: Substantiation for Dietary

³ <http://www.ncbi.nlm.nih.gov/pubmed/?term=Apoaequorin>

⁴ <http://www.ncbi.nlm.nih.gov/pubmed/?term=apoequorin+and+memory>

1 Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and
2 Cosmetic Act (“FDA Guidance of Industry”), Ex. A.

3 10. Under DSHEA, competent and reliable scientific evidence is defined
4 as: “tests, analyses, research, studies, or other evidence based on the expertise of
5 professionals in the relevant area that has been conducted and evaluated in an
6 objective manner by persons qualified to do so, using procedures generally
7 accepted in the profession to yield accurate and reliable results.” FDA Guidance of
8 Industry, Ex. A.

9 11. Plaintiff’s retained expert in brain chemistry and whether and how
10 substances may or may not affect brain function and memory, as well as other
11 experts in these fields, deem the only credible scientific evidence to substantiate
12 human health benefit claims, such as those at issue here, is evidence from high
13 quality RCTs (hereafter “competent and reliable evidence”). No such RCTs exist to
14 substantiate the brain function and memory benefits as the labeling represents that
15 Prevagen provides.

16 12. Because there is no competent and reliable evidence that Prevagen
17 provides brain function and memory benefits, Defendant is selling a dietary
18 supplement in violation of federal law, DSHEA, and California’s Sherman Act.

19 13. Defendant has employed numerous media to convey its uniform,
20 deceptive brain function and memory representations to consumers, including
21 magazines, newspapers, the internet, social media websites, and, importantly, on
22 the front of the Prevagen packaging and labeling where it cannot be missed by
23 consumers. The only reason a consumer would purchase Prevagen is to obtain the
24 advertised brain function and memory benefits, which it does not provide.
25 Prevagen is a singular purpose product – its only purported benefit is to enhance
26 brain function and memory which it does not and cannot do.

27 14. As a result of Defendant’s deceptive and unlawful brain function and
28

1 memory representations, consumers – including Plaintiff and members of the
2 proposed Class – have purchased Products that do not perform as advertised.

3 15. Plaintiff brings this action on behalf of himself and other similarly
4 situated consumers who purchased Prevagen, to halt the dissemination of this false,
5 misleading and deceptive advertising message, correct the false and misleading
6 perception it has created in the minds of consumers, and obtain redress for those
7 who have purchased Prevagen. Based on violations of state unfair competition laws
8 (detailed below), Plaintiff seeks injunctive and restitutionary relief for consumers
9 who purchased Prevagen.

10 16. Plaintiff also brings this action on behalf of himself and other similarly
11 situated California consumers who have purchased Prevagen under the “unlawful”
12 prong of the UCL. Plaintiff seeks to halt Defendant’s unlawful sale of Prevagen in
13 violation of applicable FDA law and regulations and California’s Sherman Act and
14 also seeks full restitution of Plaintiff’s and other California consumers’ full
15 purchase price.

16 JURISDICTION AND VENUE

17 17. This Court has original jurisdiction pursuant to 28 U.S.C. §1332(d)(2).
18 The matter in controversy, exclusive of interest and costs, exceeds the sum or value
19 of \$5,000,000 and is a class action in which there are in excess of 100 class
20 members and some members of the Class are citizens of a state different from
21 Defendant.

22 18. This Court has personal jurisdiction over Defendant because
23 Defendant is authorized to conduct and does business in California, including this
24 District. Defendant marketed, promoted, distributed, and sold Prevagen in
25 California and Defendant has sufficient minimum contacts with this State and/or
26 sufficiently availed itself of the markets in this State through its promotion, sales,
27 distribution and marketing within this State, including this District, to render the
28

1 exercise of jurisdiction by this Court permissible.

2 19. Venue is proper in this Court pursuant to 28 U.S.C. §§1391(a) and (b)
3 because a substantial part of the events giving rise to Plaintiff's claims occurred
4 while he resided in this judicial district. Venue is also proper under 18 U.S.C.
5 §1965(a) because Defendant transacts substantial business in this District.

6 **PARTIES**

7 20. During the relevant time period, Plaintiff Phillip Racies resided in
8 Petaluma, California. On September 25, 2014, Plaintiff Racies was exposed to and
9 saw Defendant's brain function and memory representations by reading the
10 Prevagen Regular Strength label. Plaintiff Racies purchased and consumed
11 Prevagen Regular Strength at a Walgreens in San Rafael, California in reliance on
12 Defendant's material brain function and memory representations. He paid
13 approximately \$27.99 for the Product. The Prevagen Regular Strength product
14 Plaintiff Racies purchased did not and could not improve memory or support
15 healthy brain function as represented. As a result, Plaintiff Racies suffered injury in
16 fact and lost money. Had Plaintiff Racies known the truth about Defendant's
17 misrepresentations, he would not have purchased Prevagen. Furthermore, Plaintiff
18 was injured when he was induced to purchase a product that but for Defendant's
19 unlawful sale of the Product would not be available for purchase.

20 21. Defendant Quincy Bioscience, LLC is a limited liability company
21 organized and existing under the laws of the state of Wisconsin. Quincy
22 Bioscience, LLC's headquarters is at 301 South Westfield Road, Suite 200, in
23 Madison, Wisconsin. The sole member of Quincy Bioscience, LLC is Quincy
24 Bioscience Holding Company, Inc. Quincy Bioscience Holding Company, Inc. is a
25 Wisconsin corporation. Defendant Quincy Bioscience, LLC is therefore a citizen of
26 Wisconsin. Defendant Quincy Bioscience, LLC manufactures, advertises markets,
27 distributes, and/or sells Prevagen to tens of thousands of consumers in California


and throughout the United States

FACTUAL ALLEGATIONS

Prevagen

22. Since at least the fall of 2007, Defendant has manufactured, distributed, marketed and sold Prevagen. The Products are marketed as a supplement with the singular purpose of providing key brain health benefits, including improving age-related memory loss.

23. Prevagen is sold in virtually every major food, drug, and mass retail outlet in the country. It is also sold on-line at Defendant's website. Prevagen is available in regular strength, extra strength and mixed berry flavor chewable forms. The regular strength and mixed berry flavor products contain 10 mg of apoaequorin per serving, while the extra strength product contains 20 mg of apoaequorin per serving. A 30-count bottle of Prevagen retails for approximately \$28.00 - \$40.00. The following are screen shots of the Products:



24. Throughout the relevant time period, Defendant has consistently conveyed the message to consumers throughout the United States, including California, that Prevagen is “clinically tested” to “improve[] memory” and


“support[]: healthy brain function, shaper mind, and clearer thinking” and is “clinically tested” to “improve memory within 90 days” simply by taking the recommended daily dosage. It does not. Defendant’s brain function and memory representations are false, misleading and deceptive.

25. Despite the evidence the Prevagen does not and cannot improve memory or support brain function, sharper mind or clearer thinking, each and every Product package and label repeatedly emphasizes that Prevagen is “clinically tested” to “improve[] memory” and “support[]: healthy brain function, shaper mind, and clearer thinking” and is “clinically tested” to “improve memory within 90 days”. Each and every consumer who purchases these Products is exposed to the deceptive brain function and memory representations, which appear prominently and conspicuously on the front and/or back of each Prevagen box as follows:



26. The side and back of the Prevagen box repeat the “clinically tested” brain function and memory representations:


SIDE



BACK

Clinically Tested

In a computer assessed, double-blinded, placebo controlled study, Prevagen® improved memory.*



Originally discovered in jellyfish, Prevagen® is now made in a controlled scientific process. Developed by university researchers and scientists in Madison, Wisconsin.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

27. And, on the top of the Prevagen box is a picture of the brain encircled by the “supports healthy brain function” representation:



Copies of the labels are attached hereto as Exhibit B.

Defendant is Unlawfully Selling Prevagen in Violation of Federal and State Law

28. Prevagen is a dietary supplement and governed by DSHEA.

29. DSHEA permits the makers of dietary supplements to make claims as to how their supplement affects the structure or function of the body without obtaining prior FDA approval provided certain requirements are met. 21 U.S.C. §§342, 343. One of these requirements is that the manufacturer must have substantiation that the claims are truthful and not misleading. 21 U.S.C. §343(r)(6)(B).

30. California's Sherman Food, Drug, and Cosmetic Law ("Sherman Act") (California's Health & Safety Code §§109875, et. seq.), parallels the FDCA in material part and adopts the Federal requirements for dietary supplements, including that dietary supplement claims be made in accordance with Section 403(r)(6) of the FDCA. Cal. Health & Safety Code § 110100(a).

31. The FDA has adopted the FTC's substantiation standard of "competent and reliable scientific evidence" for dietary supplements as described above.

32. Competent and reliable scientific evidence is defined as: "tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area that has been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results." FDA Guidance of Industry, Ex. A. For products such as Prevagen, adequate substantiation, as required by experts in the relevant area, consists of high quality RCTs – particularly when representations regarding health affects is the subject matter.

33. There are no reliable or high quality RCTs substantiating any of the representations made by Defendant about Prevagen.

34. By selling Prevagen without the prerequisite competent and reliable scientific evidence/substantiation for these representations, Defendant has violated

DSHEA and the Sherman Act.

The Impact of Defendant's Wrongful Conduct

35. Plaintiff and Class members have been and will continue to be deceived or misled by Defendant's deceptive brain function and memory representations. Plaintiff and the Class members have been damaged in their purchases of these Products and have been deceived into purchasing Products that they believed, based on Defendant's representations, improved memory and supported brain function, sharper mind and clearer thinking, when, in fact, they do not.

CLASS DEFINITION AND ALLEGATIONS

36. Plaintiff brings this action on behalf of himself and all other similarly situated Class members pursuant to Rule 23(a), (b)(2) and (b)(3) of the Federal Rules of Civil Procedure and seeks certification of the following Class against Defendant for violations of California state laws and/or similar laws in other states:

Multi-State Class Action

All consumers who, within the applicable statute of limitations period, purchased Prevagen in California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New York, and Washington until the date notice is disseminated.

Excluded from this Class are Defendant and its officers, directors and employees and those who purchased Prevagen for the purpose of resale.

37. Alternatively, Plaintiff brings this action on behalf of himself and all other similarly situated California consumers pursuant to Rule 23(a), (b)(2) and (b)(3) of the Federal Rules of Civil Procedure and seeks certification of the following Class:

California-Only Class Action

All California consumers who, within the applicable statute of limitations, purchased Prevagen until the date notice is disseminated.

1 Excluded from this Class are Defendant and its officers,
2 directors and employees, and those who purchased
3 Prevagen for the purpose of resale.

4 38. **Numerosity.** The members of the Class are so numerous that joinder
5 of all members of the Class is impracticable. Plaintiff is informed and believes that
6 the proposed Class contains thousands of purchasers of Prevagen who have been
7 damaged by Defendant's conduct as alleged herein. The precise number of Class
8 members is unknown to Plaintiff.

9 39. **Existence and Predominance of Common Questions of Law and**
10 **Fact.** This action involves common questions of law and fact, which predominate
11 over any questions affecting individual Class members. These common legal and
12 factual questions include, but are not limited to, the following:

- 13 (a) whether Defendant's representations discussed above are misleading,
14 or objectively reasonably likely to deceive;
- 15 (b) whether Defendant's alleged conduct is unlawful;
- 16 (c) whether the alleged conduct constitutes violations of the laws asserted;
- 17 (d) whether Defendant engaged in false or misleading advertising; and
- 18 (e) whether Plaintiff and Class members are entitled to other appropriate
19 remedies, including restitution, corrective advertising and injunctive relief.

20 40. **Typicality.** Plaintiff's claims are typical of the claims of the members
21 of the Class because, *inter alia*, all Class members were injured through the
22 uniform misconduct described above and were subject to Defendant's deceptive
23 brain function and memory representations that accompanied each and every bottle
24 of Prevagen. Plaintiff is also advancing the same claims and legal theories on
25 behalf of himself and all members of the Class.

26 41. **Adequacy of Representation.** Plaintiff will fairly and adequately
27 protect the interests of the members of the Class. Plaintiff has retained counsel
28 experienced in complex consumer class action litigation, and Plaintiff intends to

1 prosecute this action vigorously. Plaintiff has no adverse or antagonistic interests
2 to those of the Class.

3 42. **Superiority.** A class action is superior to all other available means for
4 the fair and efficient adjudication of this controversy. The damages or other
5 financial detriment suffered by individual Class members is relatively small
6 compared to the burden and expense that would be entailed by individual litigation
7 of their claims against Defendant. It would thus be virtually impossible for
8 members of the Class, on an individual basis, to obtain effective redress for the
9 wrongs done to them. Furthermore, even if Class members could afford such
10 individualized litigation, the court system could not. Individualized litigation
11 would create the danger of inconsistent or contradictory judgments arising from the
12 same set of facts. Individualized litigation would also increase the delay and
13 expense to all parties and the court system from the issues raised by this action. By
14 contrast, the class action device provides the benefits of adjudication of these issues
15 in a single proceeding, economies of scale, and comprehensive supervision by a
16 single court, and presents no unusual management difficulties under the
17 circumstances here.

18 43. Plaintiff seeks preliminary and permanent injunctive and equitable
19 relief on behalf of the entire Class, on grounds generally applicable to the entire
20 Class, to enjoin and prevent Defendant from engaging in the acts described, and
21 requiring Defendant to provide full restitution to Plaintiff and Class members.

22 44. Unless a Class is certified, Defendant will retain monies received as a
23 result of its conduct that were taken from Plaintiff and Class members. Unless a
24 Class-wide injunction is issued, Defendant will continue to commit the violations
25 alleged, and the members of the Class and the general public will continue to be
26 deceived.

27 45. Defendant has acted and refused to act on grounds generally applicable
28

1 to the Class, making appropriate final injunctive relief with respect to the Class as a
2 whole.

3 **COUNT I**

4 **Violation of Business & Professions Code §17200, *et seq.*** 5 **Unlawful Business Acts and Practices** 6 **(On Behalf of the California-Only Class)**

7 46. Plaintiff repeats and re-alleges the allegations contained in the
8 paragraphs above, as if fully set forth herein.

9 47. Plaintiff brings this claim individually and on behalf of the California-
10 Only Class.

11 48. The Unfair Competition Law, Business & Professions Code §17200, *et*
12 *seq.* (“UCL”), prohibits any “unlawful” business act or practice.

13 49. As alleged herein, Defendant engaged in illegal conduct by unlawfully
14 making the representations set forth above. Because Defendant did not have
15 adequate substantiation that these representations were truthful and not misleading
16 Defendant has committed unlawful business practices by violating California’s
17 Sherman Food, Drug and Cosmetic Law, California’s Health & Safety Code §§
18 109875, *et seq.* and the Food Drug and Cosmetic Act, 21 U.S.C. §§ 301, *et seq.*
19 Plaintiff and the California-Only Class reserve the right to allege other violations of
20 law, which constitute other unlawful business acts or practices. Such conduct is
21 ongoing and continues to this date.

22 50. Plaintiff and the California-Only Class suffered “injury in
23 fact”/economic loss by spending money on a Product that, but for Defendant’s
24 illegal conduct, would not have been on the market.

25 51. The FDA and Sherman Act misbranding/consumer protections are
26 intended to ensure that any claims made about dietary supplements, as defined
27 under the FDA law and regulations, to the consuming public (e.g., sold to Plaintiff
28

1 and the California-Only Class), are truthful and not misleading.

2 52. The UCL unlawful prong is intended to hold a defendant who violates
3 this prong accountable for its violations by, among other things, paying full
4 compensation to purchasers who have purchased the illegally sold products.

5 53. But for Defendant unlawfully selling Prevagen, Plaintiff and the
6 California Class would never have purchased the illegal Products. As result of
7 Defendant's illegal conduct, Plaintiff and the California-Only Class have suffered
8 injury/economic loss and are entitled to a full refund of their purchase price. Unless
9 restrained and enjoined, Defendant will continue to engage in the illegal sale of the
10 Products. Accordingly, injunctive relief is appropriate.

11 54. Plaintiff, on behalf of himself, all other similarly situated California
12 consumers, and the general public, seeks restitution of all money paid for
13 Defendant's illegally sold Products, an injunction prohibiting Defendant from
14 continuing to sell the Products without adequate substantiation, corrective
15 advertising and all other relief this Court deems appropriate, consistent with
16 Business & Professions Code §17203.

17 **COUNT II**

18 **Violation of Business & Professions Code §17200, *et seq.***
19 **Fraudulent Business Acts and Practices**
20 **(On Behalf of the Multi-State or California-Only Class)**

21 55. Plaintiff repeats and re-alleges the allegations contained in the
22 paragraphs above, as if fully set forth herein.

23 56. Plaintiff brings this claim individually and on behalf of the Class.

24 57. As alleged herein, Plaintiff has suffered injury in fact and lost money
25 or property as a result of Defendant's conduct because he purchased Prevagen in
26 reliance on Defendant's claim that the Product would provide brain function and
27 memory benefits, but did not receive a Product that provides these benefits.

1 58. The Unfair Competition Law, Business & Professions Code §17200, et
2 seq. (“UCL”), and similar laws in the other class states, prohibits any “fraudulent”
3 business act or practice and any false or misleading advertising.

4 59. In the course of conducting business, Defendant committed
5 “fraudulent business act[s] or practices” and false or misleading advertising by,
6 *inter alia*, making the brain function and memory representations (which also
7 constitutes advertising within the meaning of §17200) regarding the Products in its
8 advertising campaign, including the Products’ packaging, as set forth more fully
9 herein.

10 60. Defendant’s actions, claims and misleading statements, as more fully
11 set forth above, are false, misleading and/or likely to deceive the consuming public
12 within the meaning of Business & Professions Code §17200, et seq.

13 61. Plaintiff and other members of the Class have in fact been deceived as
14 a result of their reliance on Defendant’s material brain function and memory
15 representations. Plaintiff and the other Class members have suffered injury in fact
16 and lost money as a result of their purchase(s) of Defendant’s Products which do
17 not provide brain function or memory benefits.

18 62. Unless restrained and enjoined, Defendant will continue to engage in
19 the above-described conduct. Accordingly, injunctive relief is appropriate.

20 63. Plaintiff, on behalf of himself, all others similarly situated, and the
21 general public, seeks restitution of all money obtained from Plaintiff and the
22 members of the Class collected as a result of unfair competition, an injunction
23 prohibiting Defendant from continuing such practices, corrective advertising and all
24 other relief this Court deems appropriate, consistent with Business & Professions
25 Code §17203.

26 ///

27 ///

COUNT III

**Violations of the Consumers Legal Remedies Act – Civil Code §1750 *et seq.*
(On Behalf of the California-Only Class)**

64. Plaintiff repeats and re-alleges the allegations contained in the paragraphs above, as if fully set forth herein.

65. Plaintiff brings this claim individually and on behalf of the California-Only Class.

66. This cause of action is brought pursuant to the Consumers Legal Remedies Act, California Civil Code §1750, *et seq.* (the “Act”).

67. Plaintiff is a consumer as defined by California Civil Code §1761(d). Prevagen is a “good” within the meaning of the Act.

68. Defendant violated and continues to violate the Act by engaging in the following practices proscribed by California Civil Code §1770(a) in transactions with Plaintiff and the California-Only Class which were intended to result in, and did result in, the sale of Prevagen:

(5) Representing that [Prevagen has] . . . approval, characteristics, . . . uses [and] benefits . . . which [it does] not have

* * *

(7) Representing that [Prevagen is] of a particular standard, quality or grade . . . if [it is] of another.

* * *

(9) Advertising goods . . . with intent not to sell them as advertised.

* * *

(16) Representing that [Prevagen has] been supplied in accordance with a previous representation when [it has] not.

69. Pursuant to California Civil Code §1782(d), Plaintiff and the California-Only Class seek a Court order enjoining the above-described wrongful

1 acts and practices of Defendant and for restitution and disgorgement.

2 70. Pursuant to §1782 of the Act, Plaintiff notified Defendant in writing by
3 certified mail of the particular violations of §1770 of the Act and demanded that
4 Defendant rectify the problems associated with the actions detailed above and give
5 notice to all affected consumers of Defendant's intent to so act. A copy of the letter
6 is attached hereto as Exhibit C.

7 71. If Defendant fails to rectify or agree to rectify the problems associated
8 with the actions detailed above and give notice to all affected consumers within 30
9 days of the date of written notice pursuant to §1782 of the Act, Plaintiff will amend
10 this Complaint to add claims for actual, punitive and statutory damages, as
11 appropriate.

12 72. Defendant's conduct is fraudulent, wanton and malicious.

13 73. Pursuant to §1780(d) of the Act, attached hereto as Exhibit D is the
14 affidavit showing that this action has been commenced in the proper forum.

15 **PRAYER FOR RELIEF**

16 Wherefore, Plaintiff prays for a judgment:

17 A. Certifying the Class as requested herein;

18 B. Awarding restitution and disgorgement of Defendant's revenues to
19 Plaintiff and the proposed Class members;

20 C. Awarding injunctive relief as permitted by law or equity, including:
21 enjoining Defendant from continuing the unlawful practices as set forth herein;

22 D. Ordering Defendant to engage in a corrective advertising campaign;

23 E. Awarding attorneys' fees and costs; and

24 F. Providing such further relief as may be just and proper.

25 **DEMAND FOR JURY TRIAL**

26 Plaintiff hereby demands a trial of his claims by jury to the extent authorized
27 by law.

1 Dated: January 21, 2015

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

/s/Patricia N. Syverson

Elaine A. Ryan (*To be Admitted Pro Hac Vice*)
Patricia N. Syverson (203111)
Lindsey M. Gomez-Gray (*To be Admitted Pro Hac*
Vice)
2325 E. Camelback Rd., Suite 300
Phoenix, AZ 85016
eryan@bffb.com
psyverson@bffb.com
lgomez-gray@bffb.com
Telephone: (602) 274-1100

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

Manfred P. Muecke (222893)
600 W. Broadway, Suite 900
San Diego, California 92101
mmuecke@bffb.com
Telephone: (619) 756-7748

STEWART M. WELTMAN, LLC

Stewart M. Weltman (*To be Admitted Pro Hac*
Vice)
53 W. Jackson Suite 364
Chicago, IL 60604
sweltman@weltmanlawfirm.com
Telephone: (312) 588-5033

Attorneys for Plaintiff

EXHIBIT A

[Home](#) [Food](#) [Guidance & Regulation](#) [Guidance Documents & Regulatory Information by Topic](#) [Dietary Supplements](#)

Food

Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act

Contains Nonbinding Recommendations

December 2008

Additional copies are available from:
Office of Nutrition, Labeling, and Dietary Supplements
HFS-800
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740
(Tel) 301-436-2375 (Updated phone: 240-402-2375)
<http://www.cfsan.fda.gov/guidance.html>

You may submit written or electronic comments regarding this guidance at any time. Submit written comments on the guidance to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>¹. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Food Safety and Applied Nutrition
December 2008

OMB Control No. 0910-0626
Expiration Date: 08/31/2011
See additional PRA statements in [Section III](#) of this guidance

Contains Nonbinding Recommendations

Table of Contents

- I. [Introduction](#)
- II. [Discussion](#)
- III. [Paperwork Reduction Act of 1995](#)

Contains Nonbinding Recommendations

Guidance for Industry⁽¹⁾ Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate telephone number listed on the title page of this guidance.

I. Introduction

A. What Does This Guidance Document Address?

Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 343(r)(6)) requires that a manufacturer of a dietary supplement making a nutritional deficiency, structure/function, or general well-being claim⁽²⁾ have substantiation that the claim is truthful and not misleading.⁽³⁾

This guidance document is intended to describe the amount, type, and quality of evidence FDA recommends a manufacturer have to substantiate a claim under section 403(r) (6) of the Act. This guidance document is limited to issues pertaining to substantiation under section 403(r)(6) of the Act; it does not extend to substantiation issues that may exist in other sections of the Act.⁽⁴⁾

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

B. Why Is Guidance on Substantiation Helpful?

The Act, as amended by the Dietary Supplement Health and Education Act of 1994 (DSHEA) and the legislative history accompanying DSHEA do not define "substantiation." For this guidance, we drew upon our own expertise with respect to the regulations and case law regarding substantiation of various statements that may be made in the labeling of dietary supplements, conventional foods, and drug products (recognizing that conventional foods and drugs are regulated differently from dietary supplements), the Federal Trade Commission's (FTC) experience with its policy on substantiating claims made for dietary supplements in advertising, and recommendations from the Commission on Dietary Supplement Labels.

The Commission on Dietary Supplement Labels (the Commission), a seven-member body that was established under DSHEA to "provide recommendations for...the regulation of label claims and statements for dietary supplements, including the use of literature in connection with the sale of dietary supplements and procedures for the evaluation of such claims," held public meetings around the United States from 1996 through 1997. During these meetings, several manufacturers asked the Commission to provide guidance regarding the type of information that manufacturers should have in hand to substantiate a statement of nutritional support.⁽⁵⁾

Under the Act, FDA has exclusive jurisdiction over the safety, and primary jurisdiction over the labeling, of dietary supplements. The FTC has primary jurisdiction over advertisements for dietary supplements. Given these jurisdictional assignments, we and the FTC share an interest in providing guidance on what "substantiation" means. In April 2001, FTC issued a guidance document entitled, "Dietary Supplements: An Advertising Guide for Industry."⁽⁶⁾ Our guidance document is modeled on, and complements, the FTC guidance document.

Dietary supplement manufacturers should be familiar with the requirements under both DSHEA and the Federal Trade Commission Act that they have substantiation that labeling and advertising claims are truthful and not misleading. Our approach provides manufacturers flexibility in the precise amount and type of evidence that constitutes adequate substantiation. Providing a standard for substantiation may also help to preserve consumer confidence in these products. To ensure compliance with the Act, we recommend that dietary supplement manufacturers carefully draft their labeling claims and carefully review the support for each claim to make sure that the support relates to the specific product and claim, is scientifically sound, and is adequate in the context of the surrounding body of evidence.

The FTC has typically applied a substantiation standard of "competent and reliable scientific evidence" to claims about the benefits and safety of dietary supplements and other health-related products. FDA intends to apply a standard for the substantiation of dietary supplement claims that is consistent with the FTC approach. This guidance document, using examples of claims that might be made for a dietary supplement, describes criteria to be considered in evaluating the nature of the claim and the amount, type, and quality of evidence in support of the claim.

II. Discussion

A. What is the Substantiation Standard?

The FTC standard of competent and reliable scientific evidence has been defined in FTC case law as "tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that has been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results."⁽⁷⁾

Although there is no pre-established formula as to how many or what type of studies are needed to substantiate a claim, we, like the FTC, will consider what the accepted norms are in the relevant

research fields and consult experts from various disciplines. If there is an existing standard for substantiation developed by a government agency or other authoritative body, we may accord some deference to that standard.

In determining whether the substantiation standard has been met with competent and reliable scientific evidence, we recommend that firms consider the following issues in their assessment:

1. The meaning of the claim(s) being made;
2. The relationship of the evidence to the claim;
3. The quality of the evidence; and
4. The totality of the evidence.

Each of these issues is discussed further in this guidance.

B. Identifying the Meaning of the Claim

The first step in determining what information is needed to substantiate a claim for a dietary supplement is to understand the meaning of the claim and to clearly identify each implied and express claim. When a claim may have more than one reasonable interpretation, we recommend that a firm have substantiation for each interpretation. Consumer testing may be useful to determine consumer understanding of each claim, in context. We recommend that firms not only focus on individual statements or phrases, but also on what expected effect or benefit are being promoted when all of the statements being made for the product are considered together. Although it is important that individual statements be substantiated, it is equally important to substantiate the overall "message" contained when the claims are considered together.

Example 1: The label of a dietary supplement containing "X" uses the following claims: "The amino acid 'X' is the chemical precursor to nitric oxide. Blood vessel cells contain enzymes that produce nitric oxide. Nitric oxide is important in maintaining blood vessel tone." Assuming this statement were supported by sound science so that each individual statement was substantiated, the "message" conveyed by the claims, when considered together, is that taking oral "X" will affect nitric oxide production and blood vessel tone. Therefore, we recommend in this case that the dietary supplement manufacturer have substantiation that taking the amount of "X" provided by the product affect nitric oxide production and blood vessel tone under the product's recommended conditions of use.

The firm's clear understanding of the meaning of the claim is useful in ensuring that the evidentiary basis for substantiation is appropriate for the claim. Understanding the claim's meaning will help identify the appropriate study hypotheses and measurable endpoints, which can be used to ensure that the firm has appropriate studies to substantiate the claim. For example, a firm making a claim that a dietary supplement "helps maintain blood vessel tone" or "supports healthy immune system" should have a clear understanding of the claim's meaning to develop endpoints that could be measured and replicated in studies used as a basis for substantiation.

Example 2: The labeling of a dietary supplement includes the statement "promotes weight loss." The dietary supplement contains various vitamins and minerals and a botanical extract. The manufacturer relies on a randomized controlled double blind clinical study showing that subjects who took the botanical extract had a small but significant increase in metabolism over subjects taking a placebo over a 24 hour period. The study did not examine the effect of the extract on subjects' weight and there is no research showing that a short term increase in metabolism will translate into any measurable weight loss. The weight loss claim would likely not be adequately substantiated.

Example 3: The labeling for a dietary supplement contains a statement saying, "Recommended by Scientists," in connection with the product's claim. The statement gives consumers the impression that there is a body of scientists, qualified experts, who believe that the claim being made is supported by evidence. Consumers might also reasonably interpret the statement as meaning that there is general scientific agreement or consensus regarding the claim. If the manufacturer does not possess evidence to demonstrate such a consensus, the claim may not be substantiated. The opinion of a single scientist or small group of scientists is probably not adequate substantiation for such a claim.

Example 4: The labeling states, in connection with the product's claim, that the dietary supplement has been "studied for years" in a particular country or region and is the subject of clinical or "university" research. Here, the labeling conveys the impression that the product has been studied and also conveys the impression that there is a substantial body of competently conducted scientific research supporting the claim. We recommend that manufacturers possess evidence to substantiate both the express statements and their implied meaning.

C. The Relationship of the Evidence to the Claim

Whether studies or evidence have a relationship to the specific claim being made or to the dietary

supplement product itself is an important consideration in determining if a claim is substantiated. The following are some threshold questions in determining this relationship:

- *Have the studies specified and measured the dietary supplement that is the subject of the claim?* We recommend that the studies being used as substantiation for dietary supplement claims identify a specific dietary supplement or ingredient and serving size and that the conditions of use in the studies are similar to the labeling conditions of the dietary supplement product. Factors that would tend to indicate a stronger relationship between a substance that is the subject of a study and the substance that is the subject of the dietary supplement claim includes similarities in formulation, serving size, route of administration, total length of exposure, and frequency of exposure. Manufacturers should be aware that other substances involved in the study or included in the dietary supplement product itself might also affect the dietary supplement's performance or the study results.

Example 5: To illustrate this issue, assume that a firm has high quality studies that are also consistent with the totality of the scientific evidence. The firm would like to use these studies to substantiate a claim that its dietary supplement has a particular effect on the human body, but the studies involved the impact of a specific ingredient in foods on the human body, and did not involve the dietary supplement product itself. In this instance, although the studies might be of high quality, the results of these studies of conventional foods are not applicable to the specific dietary supplement product.⁽⁸⁾

- *Have the studies appropriately specified and measured the nutritional deficiency, structure/function, or general well-being that is the subject of the claim?* We recommend that the studies clearly identify the endpoints that are to be used to substantiate the claimed effect.
- *Were the studies based on a population that is similar to that which will be consuming the dietary supplement product?* For example, if the study involved young adults, but the product's claims involve conditions seen only in the elderly, the study might not be applicable to the claims.
- *Does the claim accurately convey to consumers the extent, nature, or permanence of the effect achieved in the relevant studies and the level of scientific certainty for that effect?*

A note on foreign research: Foreign research could be sufficient to substantiate a claim as long as the design and implementation of the foreign research are scientifically sound and the foreign research pertains to the dietary supplement at issue. In evaluating data from studies conducted in a foreign population, care should be taken in extending the results to what might be expected in consumers in the United States who will use the product. Differences between the two populations, such as differences in diets, general health, or patterns of use, could confound the results. Also, it is important to make sure that the study examined the same dietary ingredient about which the claim is being made since there may be instances where, due to provincial or regional differences in custom, language, or dialect, the same name is given to different substances or different names to the same substance.

Example 6: A firm claims that its dietary supplement contains an ingredient shown to promote claim Y. The firm conducts a literature search and finds several references for carefully conducted, well-controlled studies demonstrating that the substance appears to be helpful in persons with claim Y associated with aging when the substance is applied topically to the affected area. However, there is no information provided concerning the effect of the substance when taken orally. Although the evidence may demonstrate that the product is effective when used topically, this information would generally not be useful to substantiate a claim for a dietary supplement (by definition, a product that is intended for ingestion (section 201(ff)(2)(A) of the Act (21 U.S.C. 321(ff)(1)(A))).

Example 7: A dietary supplement firm wants to promote an amino acid product to improve blood circulation and improve sexual performance. The firm conducts a literature search and finds many abstracts and articles about the amino acid's effect on biological mediators of circulation and a few animal and human studies designed to study the effect of the amino acid on blood flow. The firm intends to use this list of studies as substantiation for its claim.

Although the firm appears to have a significant amount of information for its claim, the list is likely not adequate because the firm has not demonstrated that the information is directly related to the claim being made. For example, in this situation we would recommend that the firm provide information to clarify the meaning of "improves blood circulation" and "improves sexual performance." We would also recommend that the firm determine whether the studies examined a dosage of product similar to the firm's product and whether any study measured outcomes (i.e., improved sexual performance) other than blood flow/blood circulation. Until the firm has reviewed the underlying studies, it should not assume that merely finding studies testing the same substance necessarily constitutes adequate substantiation.

Example 8: A firm wishes to market its mineral supplement by using a claim that "studies show that the mineral supplement promotes "Z." The firm has the results of a randomized, double blind, placebo-

controlled study conducted in a foreign country showing that a similar product did, in fact, promote "Z," although the study indicates that the foreign study subjects had low blood levels of the mineral at the start of the study. The general U.S. population does not have such a mineral deficiency. Although this study is a high quality study, it may not be adequate to substantiate a claim about the product's use intended for consumers in the United States because it is confounded by the initial abnormal blood levels of the mineral. Since the study is not designed to answer the question of whether the effect would be expected to occur in subjects with normal blood levels of the mineral, the study may not be adequate evidence to substantiate the claim.

Example 9: A firm is marketing a product specifically to reduce nervousness during stressful everyday situations, such as public speaking. The firm has results from several small studies demonstrating that the product will raise blood levels of a chemical that is well known to relax people in stressful situations. The firm also has two small, randomized, placebo-controlled studies showing that its product positively affected measurable indices of anxiety in people placed in stressful situations, including public speaking. These studies may be adequate evidence to support the product claims. Although the studies may be small in terms of the numbers of subjects tested, they are well-designed studies that resulted in statistically significant positive results that are consistent with the larger body of scientific evidence related to stress anxiety in public situations.

Example 10: A firm has developed a product to improve memory and cognitive ability and intends to market the product to parents for their school-aged children. The firm has several high quality clinical studies that examined the ingredient's effect in elderly people with diagnosed, age-related memory problems. These studies alone would likely not be adequate substantiation for a claim about memory improvement in young children because the patient population (elderly people with memory problems) is completely different from the intended population (children) in the claim.

Example 11: A dietary supplement firm is marketing an iron dietary supplement with the claim that the dietary supplement is to correct iron-deficiency anemia in the 10% of menstruating women with menorrhagia. The firm has not studied the product in this population of women directly, but has assembled and carefully reviewed the scientific literature of studies that have investigated the oral dosage and intestinal absorption of the type of iron used in its product, both in the population in general, and in women that match the target consumer of the product. Using this information, the firm has formulated its product to provide the amount of bioavailable iron needed by this population of women. Even though the firm did not test its product directly, it has examined the existing scientific literature and has formulated the product in a manner to meet the standards of products shown effective in well-controlled studies. There is, therefore, a basis to conclude that the existing literature is applicable to the product in the target population in which it is intended. Thus, the firm's claim that the product will be useful in correcting iron-deficiency anemia would likely be adequately substantiated.

Example 12: A firm claims that its multi-vitamin, multi-mineral product "provides the vitamins and minerals needed to promote good health and wellness." In this case, the firm's claim is likely substantiated by the substantial scientific evidence showing that certain vitamins and minerals are essential nutrients that are needed to maintain good health, even though the firm does not have data from specific scientific studies to show that its product results in any measurable outcome. Scientific evidence studying the firm's particular product formulation probably would not be needed for this claim unless the firm were to make claims that its formulation is different or superior to other formulations or confers benefits above and beyond the benefits demonstrated to be associated with adequate intake of vitamins and minerals.

D. The Quality of the Evidence

In deciding whether studies substantiate a claim, an important consideration is the scientific quality of studies. Scientific quality is based on several criteria including study population, study design and conduct (e.g., presence of a placebo control), data collection (e.g., dietary assessment method), statistical analysis, and outcome measures. For example, if the scientific study adequately addressed all or most of the above criteria, it could be considered of high quality. Generally accepted scientific and statistical principles should be used to determine the quality of the studies used as evidence to substantiate a claim. The "gold" standard is randomized, double blind, placebo-controlled trial design. However, trials of this type may not always be possible, practical, or ethical. There are several systems available to rate scientific information.⁽⁹⁾ Firms making claims are encouraged to refer to these systems when developing substantiation for claims or relying on existing information. The following provides some commonly accepted scientific principles in evaluating the quality of scientific evidence.

What Are the Types of Evidence that May Substantiate a Claim?

As a general principle, one should think about the type of evidence that would be sufficient to substantiate a claim in terms of what experts in the relevant area of study would consider to be

competent and reliable. Competent and reliable scientific evidence adequate to substantiate a claim would consist of information derived primarily from human studies.

Human studies can be divided into two types: *intervention* studies and *observational* studies.⁽¹⁰⁾ Of these types of studies, intervention studies can provide causal evidence to substantiate the effect of a dietary supplement in humans because they can evaluate the product's direct effect in the human body. Observational studies have a more limited ability than intervention studies to distinguish relationships between a substance and the outcomes being evaluated and cannot provide causal evidence.

o *Intervention studies*

In intervention studies, an investigator controls whether the subjects receive the treatment or intervention of interest in order to test whether the intervention or treatment supports a pre-determined hypothesis. Firms should determine the hypothesis that should be supported or tested prior to identifying supportive documentation or developing a study protocol. Randomized, double blind, parallel group, placebo-controlled trials offer the greatest assessment of a relationship between a dietary supplement and an outcome. Although intervention studies are the most reliable studies for determining a cause-and-effect relationship, generalizing from such evidence on selected populations to different populations may not be scientifically valid. For example, as described in *Example 10* above, if there is evidence to demonstrate a relationship in a specific population (elderly patients with diagnosed age-related memory problems), then such evidence should not be extrapolated to a different population (children).

o *Observational studies*

In observational studies, the investigator does not have control over the exposure to the treatment or intervention of interest. In prospective observational studies, investigators recruit subjects and observe them before a particular outcome occurs. In retrospective observational studies, investigators review the records of subjects and interview subjects after the outcome has occurred. Retrospective studies are usually considered to be more vulnerable to recall bias (error that occurs when subjects are asked to remember past behaviors) and measurement error, but are less likely to require large sample size, cost, or encounter the ethical problems that may occur in prospective studies. Types of observational studies include:

- Case reports, which describe observations of a single subject or a small number of subjects.
- Case-series studies, which are a descriptive account of a series of "outcomes" observed over time and reported for a group of subjects. No control group is described.
- Case-control studies, which compare subjects with a condition (cases) to subjects who do not have the same condition (controls). Subjects are enrolled based on their outcome rather than based on their exposure.
- Cohort studies, which compare the outcome of subjects who have been exposed to the substance to the outcome of subjects who have not been exposed.
- Cross-sectional (prevalence) studies, which compare, at a single point in time, the number of individuals with a condition who have been exposed to a substance to the number of individuals without the condition who were not exposed to the substance.
- Time-series studies, which compare outcomes during different time periods, e.g., whether the rate of occurrence of a particular outcome during one five-year period changed during a subsequent five-year period.
- Epidemiological studies, which compare the rate of a condition across different populations.

What types of information are useful as background to support a claim?

The following additional types of information would generally be considered background information, but alone may not be adequate to substantiate a claim.

- o *Animal studies* - Animal studies may provide useful background on the biological effects of a substance. However, they often have limited or unknown value in predicting the effect of the substance in humans. Care should be exercised in extrapolating results obtained in animal research directly to the human condition. The strongest animal evidence is based on data from studies in appropriate animal models, on data that have been reproduced in different laboratories, and on data that give a statistically significant dose-response relationship. Without any data from human studies, the results of animal studies alone are not sufficient to substantiate a claim.
- o *In vitro studies* are studies that are done outside a living body. For example, such studies might examine a product's effect on isolated cells or tissues. These studies are of limited value in predicting the effect of a substance when consumed by humans. The strongest in vitro evidence

would be based on data that have been reproduced in different laboratories, but this evidence alone would not substantiate a claim.

- *Testimonials and other anecdotal evidence* - This type of evidence includes descriptions of experiences of individuals using a dietary supplement product or ingredient. It might also include descriptions of the use of the product or ingredient by others, for example, by other cultures in the past or present. It might consist of an opinion or statement of an expert or someone who endorses the product. Anecdotal evidence generally would not be sufficient to substantiate claims regarding a dietary supplement's effect because each individual's experience might be attributable to factors other than the dietary supplement itself. For example, a person might have experienced a placebo or coincidental effect, rather than an effect attributable to the dietary supplement itself. Additionally, the "honest opinion" of a consumer testimonial or an expert endorsement would not be enough to substantiate a claim; rather, the endorsement should also be supported by competent and reliable scientific evidence.
- *Meta-analysis* is the process of systematically combining and evaluating the results of clinical trials that have been completed or terminated. Meta-analysis may identify relevant reports, which may provide substantiation for the claim.
- *Review articles* summarize the findings of primary reports. Review articles may identify relevant primary reports, which may provide substantiation for the claim. Review articles may also provide background information that is useful to understand the scientific issues about the relationship between the substance and the claimed effect.
- *Comments and Letters to the Editor* usually focus on a particular issue or issues from a study, presentation at a meeting etc. Comments generally do not present the results of a study. Comments and letters to the editor may identify relevant primary reports, which may provide substantiation for the claim. Comments and letters to the editor may also provide background information that is useful to understand the scientific issues about the relationship between the substance and the claimed effect.
- *Product monographs* are prepared by the manufacturer to convey specific information about a product such as its specifications. Product monographs may provide background information that is useful to understand the scientific issues about the relationship between the substance and the claimed effect.

Example 13: A dietary supplement claim states, "Data suggest that including Substance X in the diet may promote brain neuron health in healthy individuals." The firm cites a study in which rats were fed diets containing Substance X and the brains of all rats were examined for ischemia-induced brain damage. The study does not provide a basis that Substance X would have the same effect on brain health in otherwise healthy humans. This study alone likely would not provide adequate substantiation of the claim being made because it relies solely on animal data.

Example 14: A dietary supplement claim states, "Grain Y has been used effectively for centuries to promote gastrointestinal health." The firm has no clinical studies in humans, but has an industry monograph that relies only on historical descriptions of grain Y use by pre-modern civilizations. Although the monograph may be an accurate review of the historical use of grain Y, it would likely not constitute competent and reliable evidence to support the claim because it is not based on objective scientific evidence. Rather, it is largely anecdotal evidence that cannot be objectively evaluated to determine if it applies to the consumers who would use the product.

Example 15: A dietary supplement label claims that, in laboratory tests (i.e., in vitro tests), the enzymes in the supplement can digest up to 20 grams of protein and 15 grams of dietary fat, and the firm is promoting the supplement to assist in breaking down protein and fat that its users eat. The firm has not tested its product or the ingredients in the supplement in humans. Although this evidence may be accurate, it would generally not be adequate substantiation for the claimed effects on dietary components because it is insufficient for reaching a conclusion on whether the enzymes, when consumed, would behave equivalently in the human body. Corroborating evidence from some human studies would likely be needed to determine if the in vitro findings reflect the outcomes of the product when consumed by humans.

Example 16: A botanical product label uses the claim "improves vitality." The substantiation that the firm is relying upon consists of testimonial experience it has collected from consumers and descriptions of the botanical product's traditional use. Although the firm may have testimonial experience to back up the basic claim being made, the claimed benefit would likely not be adequately substantiated because neither source is based on scientific evidence. If the firm wants to make a claim of this type, we recommend that it have scientific evidence that some measurable outcome(s) associated with the general conditions cited in the claim is (are) significantly improved.

What Design Factors Affect the Quality of a Study?

Multiple factors should be considered in study design. These include, but are not limited to:

- *Bias, confounders, and other limitations* - Potential sources of bias include lack of appropriate randomization and blinding, the number of subjects called for in the protocol vs. the number of subjects who actually participated in the trial, demographics, adequacy of primary variables, compliance, control agent, drop-outs, statistical procedures, subgroup analysis, safety issues, and reproducibility of results. Confounders are factors that are associated with the outcome in question and the intervention and prevent the measured outcome from being attributed unequivocally to the intervention. Potential confounders include variability in the quantity of the dietary supplement being administered or the presence of other dietary ingredients that may have their own independent effects. These factors can limit the reliability of the study.
- *Quality assessment criteria* - Factors that contribute to higher quality studies include:
 - Adequacy and clarity of the design
 - The questions to be answered by the study are clearly described at the outset.
 - The methodology used in the study is clearly described and appropriate for answering the questions posed by the study.
 - The duration of the study intervention or follow-up period is sufficient to detect an effect on the outcome of interest.
 - Potential confounding factors are identified, assessed, and/or controlled.
 - Subject attrition (subjects leaving the study before the study is completed) is assessed, explained, and reasonable.
 - *Population studied*
 - The sample size is large enough to provide sufficient statistical power to detect a significant effect. (If the study is underpowered, it may be impossible to conclude that the absence of an effect is not due to chance.)
 - The study population is representative (with respect to factors such as age, gender distribution, race, socioeconomic status, geographic location, family history, health status, and motivation) of the population to which the claim will be targeted.
 - The criteria for inclusion and exclusion of study subjects were clearly stated and appropriate.
 - The study used recruitment procedures that minimized selection bias.
 - For controlled interventions, the subjects were randomized. If matching was employed to assign the subjects to control and treatment groups, appropriate demographic characteristics and other variables were used for the matching. The randomization was successful in producing similar control and intervention groups.
- *Assessment of intervention or exposure and outcomes*
 - The analytical methodology and quality control procedures to assess dietary intake are adequate.
 - The dietary supplement serving size is well defined and appropriately measured.
 - The background diets to which the dietary supplement was added, or the control and interventional diets, are adequately described, measured, and suitable.
 - In studies with cross-over designs, the "wash-out" period (the period during which subjects do not receive an intervention) between dietary supplement exposures is appropriate. Lack of a sufficient wash-out period between interventions may lead to confusion as to which intervention produced the health outcome.
 - The form and setting of the intervention are representative of the way the product will be normally used.
 - Other possible, concurrent changes in diet or health-related behavior (weight loss, exercise, alcohol intake, and smoking cessation) present during the study that could account for the outcome identified are assessed and/or controlled.
 - The study's outcomes are well defined and appropriately measured
 - Efforts were made to detect harmful as well as beneficial effects.
- *Data Analysis and Assessment*
 - Appropriate statistical analyses were applied to the data.

- "Statistical significance" was interpreted appropriately.
- Relative and absolute effects were distinguished.
- *Peer Review* - The nature and quality of the written report of the research are also important. Although studies or evidence used to substantiate a claim do not have to be published in a peer-reviewed journal or publication, such publications do give some level of assurance that qualified experts have reviewed the research and found it to be of sufficient quality and validity to merit publication. In contrast, an abstract or informal summary of an article is less reliable, because such documents usually do not give the reader enough insight into how the research was conducted or how the data were analyzed to objectively evaluate the quality of the research data and the conclusions drawn by the authors. Moreover, the mere fact that the study was published does not necessarily mean that the research is competent and reliable evidence adequate to substantiate a particular claim.

Example 17: A dietary supplement label claims, "Randomized, double blind, placebo-controlled studies demonstrate that herbal extract 'Z' is beneficial in relieving menopausal symptoms." The firm is relying on the results of more than one randomized, double blind, placebo-controlled intervention study using menopausal women as subjects, and the results of those studies are in general agreement. The claim would likely be substantiated because it relies on high quality studies in humans that directly addressed conditions described in the claim.

E. Consider the Totality of the Evidence

How Well Does the Totality of Evidence Support the Claims?

In determining whether there is adequate evidence to substantiate a claim, one should consider the strength of the entire body of evidence, including criteria such as quality, quantity (number of various types of studies and sample sizes), relevance of exposure, and consistency and replication of the findings.

To determine whether the available scientific evidence is adequate to substantiate a claim, it is important to consider all relevant research, both favorable and unfavorable. Ideally, the evidence used to substantiate a claim agrees with the surrounding body of evidence. Conflicting or inconsistent results raise serious questions as to whether a particular claim is substantiated. If conflicts or inconsistencies exist in the scientific evidence, one should determine whether there are plausible explanations for such conflicts or inconsistencies. For example, an inconsistency between two studies might be attributable to different concentrations of the dietary supplement, different test methodologies, different study populations,⁽¹¹⁾ or other factors.

There is no general rule for how many studies, or what combination of types of evidence, is sufficient to support a claim. However, the replication of research results in independently conducted studies makes it more likely that the totality of the evidence will support a claim.

Although the quality of individual pieces of evidence is important, each piece should be considered in the context of all available information; that is, the strength of the total body of scientific evidence is the critical factor in assessing whether a claim is substantiated.

Example 18: A firm intends to promote an herbal product "X" to "help maintain cognitive performance" of people who are fatigued. The firm has researched the scientific literature and found many studies that demonstrate that the botanical ingredient is effective. However, there are some studies that demonstrate no effect. Still other studies examined the botanical ingredient combined with other ingredients, typically caffeine, which demonstrated mixed positive and negative results. Many reports do not adequately describe the study participants and products examined. Consequently, it is not possible to explain the disparate results. However, the firm's review suggests that either the botanical and/or caffeine are the most likely dietary ingredients that act to maintain better cognition test results in fatigued study participants. As a result, the firm conducts a large, randomized, placebo-controlled study to compare the botanical ingredient against caffeine in the treatment of cognitive performance deficits associated with fatigue. The results demonstrate that caffeine improved cognition test results in all of the fatigued subjects that received caffeine, while test performance was unaffected in all subjects receiving the botanical ingredient. The study cannot explain the results reported in the earlier studies; however, it demonstrates that the botanical ingredient studied is most likely ineffective for improving or maintaining cognitive performance in fatigued people.

Example 19: A firm plans to promote its herbal product "to effectively relieve occasional, nocturnal leg cramps." The firm has one study demonstrating the product to be effective in ameliorating nocturnal leg cramps. The firm is also aware of several other randomized controlled trials that do not show a benefit. All these studies are of equal quality and used similar patient populations and test materials. When considered as a whole, even though some evidence to support the claim exists, the totality of the

evidence does not support the proposed claim. If no plausible explanation can be found to explain the disparate results, the available evidence would probably not be considered adequate to substantiate the claim.

Example 20: An herbal product is promoted "to help you get to sleep when you have difficulty falling asleep." The firm has one randomized, placebo-controlled study in volunteers who had trouble falling asleep. The study showed that those who used the product decreased the amount of time needed time to fall asleep. There are several other high-quality studies, however, that found that the herbal ingredient used in the product did not consistently help people get to sleep. It is not clear whether the different results of the various studies are a consequence of differences in product formulation or dosage or some other factor. Even though the firm's single study is positive, it may not provide adequate substantiation because the totality of existing evidence suggests that the herbal ingredient does not decrease time to fall asleep in persons who have trouble falling asleep. Given the contrary evidence against the claim, it is unlikely that this sleep-related claim would be substantiated for this product.

Example 21: A company plans to promote its product containing ingredient X to athletes "to improve endurance performance." There are some well-designed published studies demonstrating that other products containing ingredient X are effective, but other well-designed studies show no effect for certain products containing ingredient X. The firm sponsored a randomized, blinded, six-month study comparing its product to four other products containing ingredient X in a dose (serving size)-response fashion. The findings demonstrate that the firm's product and two other products that provided the highest amount of ingredient X per day produced substantial, statistically significant improvements in athletic endurance. When the firm compared the results of this study to prior studies, the firm concluded that the explanation for previous conflicting study results is that when the serving size of ingredient X is below a certain amount, there is no measurable benefit. Taken together, the positive results from their study, and the identification of a plausible explanation to explain why some studies showed no positive effects, would likely provide evidence to substantiate adequately the endurance performance claim for the dietary supplement.

F. Conclusion

Section 403(r)(6) of the Act requires dietary supplement manufacturers to have substantiation that structure/function, nutrient deficiency, and general well-being claims on a dietary supplement product's labeling are truthful and not misleading. To meet this statutory requirement, we recommend that manufacturers possess adequate substantiation for each reasonable interpretation of the claims. We intend to apply a standard that is consistent with the FTC standard of "competent and reliable scientific evidence" to substantiate a claim. We consider the following factors important to establish whether information would constitute "competent and reliable scientific evidence:"

- Does each study or piece of evidence bear a relationship to the specific claim(s)?
- What are the individual study's or evidence's strengths and weaknesses? Consider the type of study, the design of the study, analysis of the results, and peer review.
- If multiple studies exist, do the studies that have the most reliable methodologies suggest a particular outcome?
- If multiple studies exist, what do most studies suggest or find? Does the totality of the evidence agree with the claim(s)?

III. Paperwork Reduction Act of 1995

This guidance contains information collections that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).

The time required to complete this information collection is estimated to range from 44 to 120 hours per response, depending on the nature of the claim, including the time to review instructions, search existing data sources, gather the data needed, and complete and review the information collection. Send comments regarding this burden estimate or suggestions for reducing this burden to:

Office of Nutrition, Labeling, and Dietary Supplements, HFS-800
Center for Food Safety and Applied Nutrition
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0910-0626 (expires 08/31/2011).

- (1) The Office of Nutrition, Labeling, and Dietary Supplements in FDA's Center for Food Safety and Applied Nutrition prepared this guidance document.
- (2) Under section 403(r)(6)(A) of the Act (21 U.S.C. 343(r)(6)(A)), such a statement is one that "claims a benefit related to a classical nutritional deficiency disease and discloses the prevalence of such disease in the United States, describes the role of a nutrient or dietary ingredient intended to affect the structure or function in humans, characterizes the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or function, or describes general well-being from consumption for a nutrient or dietary ingredient...."
- (3) Comments to the Draft Guidance published November 9, 2004 (69 FR 64942), questioned the constitutionality, under the First Amendment, of the substantiation requirement in section 403(r)(6), as interpreted by the Draft Guidance. This Guidance offers FDA's non-binding interpretation of what constitutes substantiation and does not change the statutory or Constitutional requirement in any way. We believe the statutory substantiation requirement in section 403(r)(6) is constitutional under the Supreme Court's analysis governing commercial speech in *Central Hudson Gas & Electric Corp. v. Public Service Commission of New York* (447 U.S. 557 (1980)). Claims made under section 403(r)(6) are misleading when made without substantiation. The misleading nature of a claim made under section 403(r)(6) that is not substantiated cannot be cured by a disclaimer stating that the claim lacks support. For example, a product cannot claim "to promote the structure and function of the skeletal system" and then attempt to cure the misleading nature of the claim with a statement "no evidence exists that this product promotes the structure and function of the skeletal system." However, nothing in this Guidance addresses the circumstances under which a claim made under section 403(r)(6) that includes qualifying language may be substantiated.
- (4) This guidance does not discuss the criteria to determine whether a statement about a dietary supplement is a structure/function claim under section 403(r)(6) of the Act or a disease claim. Please see the *Federal Register* of January 6, 2000 (65 FR 1000, codified at 21 CFR 101.93) (www.cfsan.fda.gov/~lrd/fr000106.html) for the final rule defining structure/function claims for dietary supplements and the January 9, 2002 Small Entity Compliance Guide for structure/function claims (www.cfsan.fda.gov/~dms/scimguid.html) (Updated web reference: [Structure/Function Claims; Small Entity Compliance Guide](#)²).
- (5) See Report of the Commission on Dietary Supplement Labels, November 1997, at page 42. The Commission's recommendations on substantiation are at pages 42 through 45 of the report.
- (6) See Bureau of Consumer Protection, Federal Trade Commission, "Dietary Supplements: An Advertising Guide for Industry," April 2001 (hereinafter referred to as "FTC Advertising Guide"), available at www.ftc.gov.
- (7) See, e.g. *Vital Basics, Inc.*, C-4107 (Consent April 26, 2004); see also *In Re Schering Corp.*, 118 F.T.C. 1030, 1123 (1994).
- (8) For example, a study using a conventional food or a multi-nutrient supplement would not substantiate a single ingredient dietary supplement claim. When the substance studied contains many nutrients and substances, it is difficult to study the nutrient or food components in isolation (Sempos, et al., 1999). It is not possible to accurately determine whether any observed effects of the substance were due to: 1) the substance alone; 2) interactions between the substance and other nutrients; 3) other nutrients acting alone or together; or 4) decreased consumption of other nutrients or substances contained in foods displaced from the diet by the increased intake of foods rich in the substance at issue. Furthermore, although epidemiological studies based on the recorded dietary intake of conventional foods have indicated a benefit for a particular nutrient, it has been subsequently demonstrated in an intervention study that the single ingredient nutrient-containing dietary supplement did not confer a benefit or actually was harmful. See Lichtenstein and Russell, 2005. We note that the D.C. Circuit Court in *Pearson v. Shalala*, 164 F.3d 650, 658 (D.C. Cir. 1999) indicated that FDA had "logically determined" that the consumption of a dietary supplement containing antioxidants could not be scientifically proven to reduce the risk of cancer where the existing research had examined only foods containing antioxidants as the effect of those foods on reducing the risk of cancer may have resulted from other substances. The court, however, concluded that FDA's concern with granting antioxidant vitamins a qualified health claim could be accommodated by simply adding a prominent disclaimer noting that the evidence for such a claim was inconclusive given that the studies supporting the claim were based on foods containing other substances that might actually be responsible for reducing the risk of cancer. Id. The court noted that FDA did not assert that the dietary supplements at issue would "threaten consumer's health and safety." Id. at 656. As the agency has stated in the context of qualified health claims, that is, claims regarding the relationship between a substance and the reduced risk of a disease, there is a more fundamental problem with allowing qualified health claims for nutrients in dietary supplements based solely on studies of foods containing those nutrients than the problem the D.C. Circuit held could be cured with a disclaimer. As noted in endnote 3, even if the effect of the specific component of the food constituting the dietary supplement could be determined with certainty, recent scientific studies have shown that nutrients in food do not necessarily have the same beneficial effect when taken in the form of a dietary supplement. Such studies established either that there was no benefit when the nutrients are taken as a supplement and some studies even showed

an increased risk for the very disease the nutrients were predicted to prevent. We would expect similar issues with structure/functions claims made under § 403(r)(6). Thus, an observational study based on food does not provide competent and reliable scientific evidence for a dietary supplement and, and therefore, cannot substantiate a claim made under § 403(r)(6).

(9) See "Systems to Rate the Strength of Scientific Evidence. Evidence Report/Technology Assessment Number 47, "Agency for Healthcare Research and Quality and Research (AHRQ), Publication No. 02-E016, April 2002.

(10) See Spilker, B. *Guide to Clinical Trials*. Raven Press, New York, 1991.

(11) For example, with respect to human drug products, it is fairly well known that children and the elderly may experience different drug effects compared to those seen in the adult population. These differences may be due to physiological differences (such as hormonal differences, differences in kidney function, etc.) between children, adults, and the elderly.

This document supercedes the previous (draft) version, issued November 2004.

Page Last Updated: 07/07/2014

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility](#) [Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA](#) [No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#)
[Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry Health Professionals](#) [FDA Archive](#)



U.S. Department of **Health & Human Services**


Links on this page:

1. <http://www.regulations.gov>
2. </Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ucm103340.htm>

EXHIBIT B

Clinically Tested

In a computer assessed, double-blinded, placebo controlled study, PrevaGen® improved memory.*



Originally discovered in jellyfish, PrevaGen® is now made in a controlled scientific process. Developed by university researchers and scientists in Madison, Wisconsin.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

*Package may not be recyclable in your area.



Patent Pending

14033002M



As we age, we lose proteins that support our brain.* PrevaGen® supplements these proteins during the natural process of aging.*

- ✓ Supports Healthy Brain Function*
- ✓ Only One Capsule per Day
- ✓ Safe & Clinically Tested Ingredient

PrevaGen Chewables® is designed for great tasting mixed berry flavor.

PrevaGen Chewables® contains apoequonin, a protein which uniquely supports critical brain functions.* In clinical studies PrevaGen improved memory within 90 days.*

www.prevaGen.com

Questions? Call 888.565.5385 or visit www.prevaGen.com



PrevaGen CHEWABLES

PrevaGen
(apoequonin)
Improves Memory*

CHEWABLES
MIXED BERRY FLAVOR

SUPPORTS:

- ✓ Healthy Brain Function*
- ✓ Sharper Mind*
- ✓ Clearer Thinking*

ONCE DAILY
Dietary Supplement
30 Capsules

QUINCY BIOSCIENCE
Manufactured in the USA. Materials printed in the USA.
PRCHSWD00XV1

Supplement Facts

Serving Size: 1 tablet
Servings Per Container: 30

	Amount per Tablet	% Daily Value
Total Carbohydrate	1 g	<1%**
Apoequonin	10 mg	†

** Percent Daily Values are based on a 2,000 calorie diet.
† Daily Value not established.

Other Ingredients: Sorbitol, mannitol, natural mixed berry flavor, stearic acid, magnesium stearate, sucralose, FD+C Red No. 40, salt, acetic acid.

Manufactured & Distributed by Quincy Bioscience Holding Company, Inc.
301 S Westfield Road • Madison, WI 53717

Made without most common allergens (milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, and soybeans)

Suggested use: Take 1 tablet daily in the morning, with or without food.





Prevagen®
(apocaequorin)

As we age, we lose proteins that support our brain.* Prevagen® supplements these proteins during the natural process of aging.*

- ✓ Supports Healthy Brain Function*
- ✓ Only One Capsule per Day
- ✓ Safe & Clinically Tested

Prevagen® (apocaequorin) is clinically shown to help with mild memory problems associated with aging.*

Prevagen® contains apocaequorin, a protein which uniquely supports critical brain functions.* In clinical studies Prevagen® improved memory within 90 days.*

www.prevagen.com

Questions? Call 888.565.5385
or visit www.prevagen.com

Clinically Tested

In a computer assessed, double-blinded, placebo controlled study, Prevagen® improved memory.*



Originally discovered in jellyfish, Prevagen® is now made in a controlled scientific process. Developed by university researchers and scientists in Madison, Wisconsin.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Supplement Facts

Serving Size: 1 capsule
Servings per container: 30

Amount per capsule	% Daily Value
Apocaequorin 10 mg	†
† Daily Value not established.	

Other ingredients: white rice flour, cellulose, salt, magnesium stearate, acetic acid.

Manufactured & Distributed by Quincy Bioscience
301 S Westfield Road • Madison, WI 53717

Made without COMMON ALLERGENS

Suggested use: Take 1 vegetarian capsule daily in the morning, with or without food.



Patent Pending

Clinically Tested

Prevagen®
(apocaequorin)

Improves Memory

SUPPORTS:

- ✓ Healthy Brain Function*
- ✓ Sharper Mind*
- ✓ Clearer Thinking*

ONCE DAILY

Dietary Supplement

30 Capsules

EXHIBIT C



**BONNETT FAIRBOURN
FRIEDMAN & BALINT PC**

WILLIAM G. FAIRBOURN
VAN BUNCH⁹
ELAINE A. RYAN⁶
PATRICIA N. SYVERSON²
KIMBERLY C. PAGE⁴
WILLIAM F. KING
ANDREW M. EVANS
KEVIN R. HANGER
LAURA A. VAN BUREN

ANDREW S. FRIEDMAN
ROBERT J. SPURLOCK
ANDREW Q. EVERROAD
JONATHAN S. WALLACK
CHRISTINA L. BANNON
TONNA K. FARRAR⁸
TY D. FRANKEL
ERIC D. ZARD
AUDRA E. PETROLLE¹¹

FRANCIS J. BALINT, JR.¹⁰
C. KEVIN DYKSTRA
KATHRYN A. HONECKER³
GUY A. HANSON
MANFRED P. MUECKE⁵
T. BRENT JORDAN⁷
LINDSEY M. GOMEZ-GRAY
KENDALL K. WILSON

JERRY C. BONNETT,¹ Of Counsel
MICHAEL N. WIDENER, Of Counsel

¹Admitted Also In Colorado
²Admitted Also In California
³Admitted Also In Illinois
⁴Admitted Also In Alabama and Georgia
⁵Admitted Only In California
⁶Admitted Only In California, Kansas, Missouri
and Oregon (located In Oregon)
⁷Admitted Only In Pennsylvania
⁸Admitted Also In Colorado, Idaho, Kansas,
Missouri, Texas, Utah and Washington
⁹Admitted Also In Tennessee and West Virginia
¹⁰Admitted Also In Massachusetts and Virginia
¹¹Admitted Also In New Jersey and New York

January 21, 2015

VIA CERTIFIED MAIL
(RECEIPT NO. 7012 3460 0000 7080 8592)

Quincy Bioscience, LLC
General Counsel
301 South Westfield Road, Suite 200,
Madison, Wisconsin 53717

Re: *Racies v. Quincy Bioscience, LLC*

Dear Sir or Madam:

Our law firm together with Stewart M. Weltman, LLC represent Phillip Racies and all other consumers similarly situated in an action against Quincy Bioscience, LLC arising out of, *inter alia*, misrepresentations by Defendant to consumers that Prevacen¹ is “clinically tested” to “improve[] memory” and “support[]: healthy brain function, sharper mind, and clearer thinking” and that Prevacen is “clinically tested” to “improve memory within 90 days” (collectively, “the brain function and memory representations”).

Mr. Racies and others similarly situated purchased Prevacen unaware that the scientific evidence is that Prevacen does not and cannot improve memory or support brain function, sharper mind or clearer thinking. Thus, Defendant’s brain function and memory representations are false, misleading and reasonably likely to deceive the public. The full claims, including the facts and circumstances surrounding these claims, are detailed in the Class Action Complaint, a copy of which is enclosed and incorporated by this reference.

Defendant’s brain function and memory representations are false and misleading and constitute unfair methods of competition and unlawful, unfair, and fraudulent acts or practices, undertaken by Defendant with the intent to induce the consuming public to purchase Prevacen. The brain function and memory representations do not assist consumers; they simply mislead them.

¹ “Prevagen” or “the Product” refers to your regular strength (10 mg. apoeaquorin), extra strength (20 mg. apoeaquorin) and mixed berry chewable forms (10 mg. apoeaquorin).

January 21, 2015
Page 2

Defendant's brain function and memory representations violate California Civil Code §1770(a) under, *inter alia*, the following subdivisions:

- (5) Representing that [Prevagen has] . . . characteristics, . . . uses [or] benefits. . . which [it does] not have.

* * *

- (7) Representing that [Prevagen is] of a particular standard, quality or grade, . . . if [it is] of another.

* * *

- (9) Advertising goods . . . with the intent not to sell them as advertised.

* * *

- (16) Representing that [Prevagen has] been supplied in accordance with a previous representation when [it has] not.

California Civil Code §1770(a)(5)-(16).

Defendant's brain function and memory representations also constitute violations of California Business and Professions Code §17200, *et seq.*

While the Complaint constitutes sufficient notice of the claims asserted, pursuant to California Civil Code §1782, we hereby demand on behalf of our client and all others similarly situated that Defendant immediately correct and rectify this violation of California Civil Code §1770 by ceasing the misleading marketing campaign and ceasing dissemination of false and misleading information as described in the enclosed Complaint. In addition, Defendant should offer to refund the purchase price to all consumer purchasers of Prevagen, plus reimbursement for interest, costs, and fees.

Plaintiff will, after 30 days from the date of this letter, amend the Complaint without leave of Court, as permitted by California Civil Code §1782, to include claims for actual and punitive damages (as may be appropriate) if a full and adequate response to this letter is not received. These damage claims also would include claims under the Consumers Legal Remedies Act. Thus, to avoid further litigation, it is in the interest of all parties concerned that Defendant address these violations immediately.


Defendant must undertake all of the following actions to satisfy the requirements of California Civil Code §1782(c):

January 21, 2015
Page 3

1. Identify or make a reasonable attempt to identify purchasers of Prevagen;
2. Notify all such purchasers so identified that upon their request, Defendant will offer an appropriate remedy for its wrongful conduct, which can include a full refund of the purchase price paid for Prevagen, plus interest, costs and fees;
3. Undertake (or promise to undertake within a reasonable time if it cannot be done immediately) the actions described above for all Prevagen purchasers who so request; and
4. Cease from representing to consumers that Prevagen provides brain function and memory benefits, when there is no reasonable basis for so claiming, as more fully described in the enclosed Complaint.

We await your response.

Very truly yours,


Patricia N. Syverson
For the Firm

PNS:lmg
Enclosures

EXHIBIT D

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.
ELAINE A. RYAN (*To be Admitted Pro Hac Vice*)
PATRICIA N. SYVERSON (CA SBN 203111)
LINDSEY M. GOMEZ-GRAY (*To be Admitted Pro Hac Vice*)
2325 E. Camelback Rd. Suite 300
Phoenix, AZ 85016
eryan@bffb.com
psyverson@bffb.com
lgomez-gray@bffb.com
Telephone: (602) 274-1100

BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.
Manfred P. Muecke (CA SBN 222893)
600 W. Broadway, Suite 900
San Diego, California 92101
mmuecke@bffb.com
Telephone: (619) 756-7748

STEWART M. WELTMAN, LLC
Stewart M. Weltman (*To be Admitted Pro Hac Vice*)
53 W. Jackson Suite 364
Chicago, IL 60604
sweltman@weltmanlawfirm.com
Telephone: (312) 588-5033

Attorneys for Plaintiff

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

PHILLIP RACIES, On Behalf of
Himself and All Others Similarly
Situated,

Plaintiff,

v.

QUINCY BIOSCIENCE, LLC, a
Wisconsin limited liability
company,

Defendant.

Case No.:

CLASS ACTION

**DECLARATION OF PATRICIA N.
SYVERSON PURSUANT TO
CALIFORNIA CIVIL CODE
§1780(d)**

1 I, Patricia N. Syverson, declare as follows:

2 1. I am an attorney duly licensed to practice before all of the courts of
3 the State of California. I am a shareholder of the law firm of Bonnett, Fairbourn,
4 Friedman & Balint, P.C., the counsel of record for plaintiff in the above-entitled
5 action.

6 2. Defendant Quincy Bioscience, LLC has done and is doing business
7 in the Northern District of California. Such business includes the distributing,
8 marketing, labeling, packaging and sale of Prevagen.¹ Furthermore, Plaintiff
9 purchased Prevagen in Petaluma, California.

10 3. I declare under penalty of perjury under the laws of the State of
11 California that the foregoing is true and correct.

12 Executed this 21st day of January, 2015, at Phoenix, Arizona.

13
14 BONNETT, FAIRBOURN, FRIEDMAN
& BALINT, P.C.

15 s/Patricia N. Syverson

16 Elaine A. Ryan (*To be Admitted Pro Hac Vice*)

17 Patricia N. Syverson (CA SBN 203111)

18 Lindsey M. Gomez-Gray (*To be Admitted Pro*
Hac Vice)

2325 E. Camelback Rd. Suite 300

Phoenix, AZ 85016

eryan@bffb.com

psyverson@bffb.com

lgomez-gray@bffb.com

Telephone: (602) 274-1100

21 BONNETT, FAIRBOURN, FRIEDMAN
22 & BALINT, P.C.

23 Manfred P. Muecke (CA SBN 222893)

600 W. Broadway, Suite 900

San Diego, California 92101

mmuecke@bffb.com

Telephone: (619) 756-7748

27
28 ¹ Prevagen is available in regular strength (10 mg. apoaequorin), extra strength (20 mg. apoaequorin) and mixed berry chewable forms (10 mg. apoaequorin) (collectively "Prevagen").

1 STEWART M. WELTMAN, LLC
2 Stewart M. Weltman (*To be Admitted Pro Hac*
3 *Vice*)
4 53 W. Jackson Suite 364
5 Chicago, IL 60604
6 sweltman@weltmanlawfirm.com
7 Telephone: (312) 588-5033

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
Attorneys for Plaintiff